Long and short non-coding RNA and radiation response: a review

May, Jared M.; Bylicky, Michelle; Chopra, Sunita; Coleman, C. Norman; Aryankalayil, Molykutty J.

doi:10.1016/j.trsl.2021.02.005

Cited by 40 publications

(32 citation statements)

References 122 publications

(196 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strategies targeting circulating biomarkers, such as ncRNAs, could provide a more convenient method to evaluate plaque stability in patients with coronary heart disease [15,138,139]. There are several advantages for ncRNA application in clinical trials.…”

Section: Clinical Applicationsmentioning

confidence: 99%

Targeting non-coding RNAs in unstable atherosclerotic plaques: Mechanism, regulation, possibilities, and limitations

Yang

Wang

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) caused by arteriosclerosis are the leading cause of death and disability worldwide. In the late stages of atherosclerosis, the atherosclerotic plaque gradually expands in the blood vessels, resulting in vascular stenosis. When the unstable plaque ruptures and falls off, it blocks the vessel causing vascular thrombosis, leading to strokes, myocardial infarctions, and a series of other serious diseases that endanger people's lives. Therefore, regulating plaque stability is the main means used to address the high mortality associated with CVDs. The progression of the atherosclerotic plaque is a complex integration of vascular cell apoptosis, lipid metabolism disorders, inflammatory cell infiltration, vascular smooth muscle cell migration, and neovascular infiltration. More recently, emerging evidence has demonstrated that non-coding RNAs (ncRNAs) play a significant role in regulating the pathophysiological process of atherosclerotic plaque formation by affecting the biological functions of the vasculature and its associated cells. The purpose of this paper is to comprehensively review the regulatory mechanisms involved in the susceptibility of atherosclerotic plaque rupture, discuss the limitations of current approaches to treat plaque instability, and highlight the potential clinical value of ncRNAs as novel diagnostic biomarkers and potential therapeutic strategies to improve plaque stability and reduce the risk of major cardiovascular events.

show abstract

Section: Clinical Applicationsmentioning

confidence: 99%

Targeting non-coding RNAs in unstable atherosclerotic plaques: Mechanism, regulation, possibilities, and limitations

Yang

Wang

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…Although research into non-coding RNAs has become a hot topic, it is still a long way from clinical application. Currently, the main limitations for clinical use of non-coding RNA are as follows: 1) ncRNAs are often dynamic in the circulatory system, and the samples collected from patients in a certain period of time only represent the expression status at that time (May et al, 2021). Therefore, continuous dynamic and standardized monitoring is essential if ncRNAs are to be used as biomarkers of increased risk of RSA; however, this will lead to an increase in the cost of treatment.…”

Section: Restrictions On the Use Of Non-coding Rna In Clinicmentioning

confidence: 99%

Non-Coding RNAs Regulate Placental Trophoblast Function and Participate in Recurrent Abortion

et al. 2021

View full text Add to dashboard Cite

Recurrent spontaneous abortion (RSA) is a serious pregnancy complication with an increasing clinical incidence. The various causes of recurrent abortion are complicated. Developments in genetics, immunology, and cell biology have identified important roles of non-coding RNAs (ncRNAs) in the occurrence and progress of recurrent abortion. NcRNAs can affect the growth, migration, and invasion of placental trophoblasts by regulating cell processes such as the cell cycle, apoptosis, and epithelial-mesenchymal transformation. Therefore, their abnormal expression might lead to the occurrence and development of RSA. NcRNAs include small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), transfer, RNA (tRNA), circular RNA (cRNA), and Piwi-interacting RNA (piRNA). In this review, we discuss recent research that focused on the function and mechanism of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNA (circRNA) in regulating placental trophoblasts. The use of ncRNAs as potential diagnostic and predictive biomarkers in RSA is also discussed to provide future research insights.

show abstract

“…A recent literature survey of Salamini-Montemurri et al, has identified 215 lncRNAs being involved in OCs, of which for 157 there is experimental proof [8]. Apart from initiation, lncRNAs have been associated with many biological processes associated with metastasis [80], such as the immune response [73], radiation response [81], epithelial to mesenchymal transition (EMT) and stemness [82], cell-to-cell communication, and regulation of the microenvironment in which cells reside [77].…”

Section: The Role Of Lncrnas In Various Biological Processes Related To Ovarian Carcinogenesismentioning

confidence: 99%

“…In contrast, other lncRNAs, such as HOTAIR or TUG1, can increase radioresistance by sponging specific miRNAs. Expression of lncRNAs can also be used as biomarkers of radiation damage, as lncRNA TP53COR1, TUG1 and MEG3 have been found to be upregulated after radiation damage by multiple studies [81]. Increasing the radiation sensitivity of tumor cells or increasing radiation resistance in healthy tissues by targeting specific lncRNA targets could be a promising approach for the treatment of various cancers, including ROCs.…”

Section: The Role Of Lncrnas In Various Biological Processes Related To Ovarian Carcinogenesismentioning

confidence: 99%

(In)Distinctive Role of Long Non-Coding RNAs in Common and Rare Ovarian Cancers

Sabol

Calleja‐Agius

Fiore

et al. 2021

Cancers

View full text Add to dashboard Cite

Rare ovarian cancers (ROCs) are OCs with an annual incidence of fewer than 6 cases per 100,000 women. They affect women of all ages, but due to their low incidence and the potential clinical inexperience in management, there can be a delay in diagnosis, leading to a poor prognosis. The underlying causes for these tumors are varied, but generally, the tumors arise due to alterations in gene/protein expression in cellular processes that regulate normal proliferation and its checkpoints. Dysregulation of the cellular processes that lead to cancer includes gene mutations, epimutations, non-coding RNA (ncRNA) regulation, posttranscriptional and posttranslational modifications. Long non-coding RNA (lncRNA) are defined as transcribed RNA molecules, more than 200 nucleotides in length which are not translated into proteins. They regulate gene expression through several mechanisms and therefore add another level of complexity to the regulatory mechanisms affecting tumor development. Since few studies have been performed on ROCs, in this review we summarize the mechanisms of action of lncRNA in OC, with an emphasis on ROCs.

show abstract

Long and short non-coding RNA and radiation response: a review

Cited by 40 publications

References 122 publications

Targeting non-coding RNAs in unstable atherosclerotic plaques: Mechanism, regulation, possibilities, and limitations

Targeting non-coding RNAs in unstable atherosclerotic plaques: Mechanism, regulation, possibilities, and limitations

Non-Coding RNAs Regulate Placental Trophoblast Function and Participate in Recurrent Abortion

(In)Distinctive Role of Long Non-Coding RNAs in Common and Rare Ovarian Cancers

Contact Info

Product

Resources

About